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After a series of seven electroconvulsive shocks, mice (C57BL/6J) showed a 
marked change in their response to opiates. Although very large doses of mu agonists 
induce convulsions in normal control mice, our evidence indicated that this was 
accomplished through nonopiate mechanisms: they could not be blocked by naltrexone 
and the pattern of drug potencies (codeine > morphine > levorphanol) was not 
consistent with an opiate response. In contrast, after electroconvulsive shock small 
doses of mu agonists induced convulsions that could be blocked by naltrexone and 
the pattern of drug potency (levorphanol > morphine > codeine) was consistent 
with an opiate mechanism. Kappa drugs, on the other hand, produced convulsions 
in both control and ECS animals, although there was an enhanced responsiveness in 
the latter. Furthermore, the convulsions produced by kappa drugs were blocked by 
naltrexone and showed stereoselectivity in both control and ECS animals. The 
changes in responsiveness to mu and kappa opiates cannot be explained on the basis 
of a general increase in seizure susceptibility, as sensitivity to the nonopiate 
convulsant, strychnine, was not enhanced after electroconvulsive shock. The results 
point to a qualitative change in response to mu agonists after electroconvulsive 
shock, but only a change in sensitivity to kappa agonists. 8 1985 Academic mess, hc. 
INTRODUCTION 
Previous research in our laboratory demonstrated that animals receiving 
a series of convulsions by amygdala stimulation, metrazol, or electrocon- 
vulsive shock (ECS) showed generalized nonlethal clonic convulsions to 
doses of morphine that produced no convulsive effects in their respective 
controls (8, 9). The changes in morphine responsiveness were enduring and 
could be detected to 3 months after an animal’s last amygdala-kindled 
convulsion. Further, the morphine-induced convulsions observed in animals 
Abbreviations: ECS-electroconvulsive shock, EKC-ethylketazocine. 
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with a history of convulsions appear to be a specific action of the drug, as 
they could be blocked by small doses of opiate antagonists. 
While pursuing these effects we observed that morphine could induce 
convulsions in normal animals, but it required lethal doses and the drug- 
induced convulsions could not be blocked by pretreatment with even large 
doses (30 to 100 mg/kg) of naltrexone. It was unclear, then, whether the 
changes induced by a history of convulsions represented a qualitatively 
different response to morphine, or only a change in sensitivity. We, 
therefore, systematically examined the pharmacologic properties of the 
enhanced opiate response that follows convulsions, hypothesizing that if the 
changes were qualitative, then animals with a history of convulsions should 
respond differently to a series of opiate drugs. 
Specifically, we compared the responses of ECS and control animals to 
levorphanol, codeine, and morphine and examined whether or not the drug 
effects could be blocked by naltrexone pretreatment. Particular attention 
was paid to the pattern of drug potencies of these mu agonists in inducing 
convulsions to determine if the response was consistent with other established 
opiate effects. A change in sensitivity would be inferred if mu opiates 
produced convulsions through an opiate mechanism in both ECS and 
control animals, whereas a qualitative change would be inferred if mu 
opiates produced convulsions by an opiate mechanism only after a history 
of ECS convulsions. 
In addition, to determine if ECS also produces functional changes in 
kappa opiate receptors, we examined whether ECS animals were more 
responsive to ethylketazocine (EKC) and UM 1071, two kappa opiate 
agonists (3, 7, 17). Because we found EKC and UM 107 1 to be potent 
convulsants, we examined whether or not the convulsions showed stereo- 
selectivity and could be blocked by naltrexone pretreatment. 
As there was evidence in the literature to indicate that animals with a 
history of convulsions were more sensitive to convulsant drugs [e.g., (13)], 
we examined whether or not the enhanced responsiveness to opiates 
observed in kindled and ECS animals was due to a general increase in 
seizure proneness by determining if ECS animals were more sensitive to 
metrazol and strychine, two nonopiate convulsants. 
Lastly, the convulsion history, including the number of convulsions, the 
elapsed time from the last convulsion, and whether or not convulsions were 
essential for inducing the observed effect, was also explored. 
METHODS 
General Methods. All animals used in the following experiments were 
adult C57BL/6J mice either bought from Jackson Laboratories, Bar Harbor, 
Maine or bred in our laboratory from Jackson stock. The animals were 
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maintained on a 12-h light: 12-h dark cycle with food and water available 
ad /i&turn. All drug data points were based on a minimum of six animals 
and all testing was conducted during the first 6 h of the dark phase. 
The animals were injected i.p. and the range of doses was based on the 
results of pilot experiments. The animals were randomly assigned to a drug 
condition and tested only once. The percentage of animals showing a 
generalized convulsion, including clonic limb movements and falling, was 
recorded for each drug condition and was used as the dependent variable 
in each of the experiments. 
Unless otherwise indicated, the animals received seven daily electrocon- 
vulsive shocks and were tested 3 days after their last convulsion. The ECS 
procedure consisted of passing electricity to the cornea (6.5 mA, 0.5 s) 
through two saline-soaked gauze pads attached to two wooden dowels. The 
ECS and control animals were handled identically except that the latter 
were not shocked. 
Experiment I. Changes in Responsiveness to Mu Agonists That followed 
Electroconvulsive Shock 
Levorphanol, Morphine, and Codeine Dose-Response Curves in EC’S and 
Control Animals. Eight groups (N = 6 or 7) of ECS animals were tested 
with different doses of levorphanol (10 or 30 mg/kg), morphine (25, 60, or 
100 mg/kg), or codeine (60, 100, or 170 mg/kg). For comparison, nine 
groups (N = 6 to 8) of handled control mice were similarly tested with 
levorphanol (30, 100, or 300 mg/kg), morphine (100, 300, or 600 mg/kg), 
or codeine ( 100, 170, or 300 mg/kg). These three drugs were chosen because 
they are relatively specific mu agonists and differ widely in their potencies 
(2). The percentage of ECS and control mice that convulsed after the 
injection of levorphanol or morphine was recorded during a 90-min 
observation period. The ECS and control animals that received codeine 
were observed for only 30 min postinjection because of its short duration 
of action. 
As levorphanol failed to elicit convulsions in control mice, an additional 
group (N = 9) of animals was implanted with a bipolar electrode in the 
frontal cortex. The animals were handled for 7 days and tested with 300 
mg/kg levorphanol 3 days later to determine if levorphanol produced any 
electrographic evidence of seizures in normal animals. 
Naltrexone Blockade of Levorphanol-, Morphine-, and Codeine-Induced 
Convulsions in ECS and Control Animals. Ten groups (N = 6 to 13) of 
ECS animals were pretreated with either saline or one of several doses of 
naltrexone (0.1, 0.3, 1.0, or 3.0 mg/kg) 5 min prior to receiving either 
levorphanol (30 mg/kg), morphine (100 mg/kg), or codeine (100 mg/kg). 
We chose these doses of levorphanol, morphine, and codeine because they 
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produced no significant difference in the percentage of ECS animals 
convulsing (x = 3.0, df = 2, ns.). For comparison, nine groups (N = 6 to 
7) of control mice were pretreated with either saline or naltrexone (3.0, 
10.0, 30.0, or 100 mg/kg) 5 min prior to either morphine (600 mg/kg) or 
codeine (300 mg/kg). Larger doses of morphine and codeine were used in 
control animals in order to produce convulsions in a percentage of animals 
equivalent to that seen in ECS animals. We did not attempt to block the 
effects of levorphanol with naltrexone in control animals, for it failed to 
induce convulsions even at lethal doses. 
Experiment II. Changes in Sensitivity to Kappa Agonists 
after Electroconvulsive Shock 
Ethylketazocine and (-)UM 1071 Dose-Response Curves in ECS and 
Control Animals. Six groups (N = 6 to 8) of ECS animals were tested with 
one of several doses of EKC (1.0, 1.7, or 3.0 mg/kg) or (-)UM 1071 
(1 .O, 1.7, or 3.0 mg/kg) to determine a dose-response curve for each drug. 
Six groups (N = 6 to 8) of controls were similarly tested with either EKC 
(3.0, 6.0, or 10.0 mg/kg) or (-)UM 1071 (3.0, 6.0, or 10.0 mg/kg). The 
percentage of ECS and control mice that convulsed was recorded during a 
30-min observation period for each drug and dose condition. 
Naltrexone Blockade of EKC- and (-)UM 1071~Induced Convulsions in 
ECS and Control Animals. Eight groups (N = 7) of ECS animals were 
pretreated with either saline or one of several doses of naltrexone (0.1, 0.3, 
1.0, or 3.0 mg/kg) 5 min prior to either 3.0 mg/kg EKC or 3.0 mg/kg 
(-)UM 107 1. Seven groups (N = 6 or 7) of handled controls were similarly 
pretreated with either saline or naltrexone (0.1, 0.3, 1.0, or 3.0 mg/kg) 5 
min prior to either 10 mg/kg EKC or 10 mg/kg (-)UM 107 1. These doses 
of EKC and (-)UM 107 1 were used because they produced convulsions in 
an equivalent percentage of ECS and control animals. 
Stereospectjicity. We examined the stereospecificity of the convulsions 
induced by kappa agonists by comparing the effects of (+)UM 107 1 with 
its stereoisomer in ECS and control animals. Three groups (N = 8) of ECS 
animals were treated with either 10, 100, or 170 mg/kg (+)UM 107 1. For 
comparison, three groups (N = 6) of control animals were similarly treated 
with 100, 170, or 300 mg/kg (+)UM 107 1. The percentage of ECS and 
control mice that convulsed was recorded during a 30-min observation 
period for each dose of drug. 
Experiment III. Changes in Response to Nonopiate Convulsants That 
follow Electroconvulsive Shock 
We examined the specificity of the changes in opiate responsiveness by 
testing whether ECS animals were more sensitive to metrazol and strychnine, 
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two nonopiate convulsants. Three groups (N = 6 to 8) of ECS mice were 
tested with 40, 45, or 50 mg/kg metrazol 3 days after their last convulsion. 
Four groups (N = 6 to 8) of control animals were similarly handled and 
tested with 40, 45, 50, or 60 mg/kg metrazol. An additional four groups 
(N = 6 to 10) of ECS and control animals were tested with strychnine 
(1.0, 1.5, 1.8, or 2.0 mg/kg). The percentage of ECS and control mice that 
convulsed to metrazol or strychnine was recorded during a 30-min obser- 
vation period. 
Experiment IV. Variables Influencing the Change in Responsiveness to 
Opiates That follow Electroconvulsive Shock 
Number of Convulsions. Three groups (N = 7) of ECS animals received 
23 electroconvulsive shocks and were tested 3 days later with either 0.3, 
1.0, or 1.7 mg/kg EKC. Three groups (N = 6) of control animals were 
similarly handled for 23 days and tested 3 days later with EKC (3, 10, or 
17 mg/kg). These data were compared with those reported in experiment 
II in which mice were tested after 7 days of ECS or handling. 
Time from Last Convulsion. A group (N = 8) of ECS mice was given 
seven convulsions and tested with morphine ( 100 mg/kg) 30 days after their 
last treatment. These data were compared with those reported in experiment 
I in which animals were tested 3 days after their last convulsion. 
The Necessity of Convulsions in Producing a Change in Opiate Respon- 
siveness. Two groups of naive mice (N = 6 or 7) received a subconvulsive 
dose of EKC (1 mg/kg) for 20 consecutive days and were tested 3 days later 
with either 100 or 300 mg/kg morphine. This dose of EKC, although 
moderately large, failed to elicit a convulsion throughout the treatment 
paradigm. These animals were compared with two groups (N = 7 or 8) of 
mice that received seven convulsions induced by EKC (10 mg/kg) and were 
tested 3 days later with morphine (30 or 100 mg/kg). The 10 mg/kg dose 
of EKC induced daily convulsions in the majority of animals. 
RESULTS 
Experiment I. The dose-response curves of levorphanol, morphine, and 
codeine for ECS and control animals are presented in Fig. 1. As this figure 
shows, animals became more responsive to all three mu opiates following 
ECS. Of particular importance, the pattern of drug effects differed in the 
ECS and control animals. After ECS, levorphanol (30 mg/kg) was found 
to be more effective than morphine (25 mg/kg) (x2 = 6.2, P < 0.05) 
and morphine (60 mg/kg) was more effective than codeine (60 mg/kg) 
(x2 = 3.82, P < 0.05) in inducing convulsions. In control animals, in 
contrast, codeine (300 mg/kg) was more effective than morphine (300 mg/ 
kg) (x2 = 7.14, P < 0.0 1) in inducing convulsions, and levorphanol failed 
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FIG. I. Percentage of mice that received electroconvulsive shock (ECS) and control mice 
convulsing to morphine, levorphanol, or codeine 3 days after seven ECSs. All control animals 
were handled the same as ECS animals, but were not shocked. All data points are based on six 
or more animals; total number of animals per drug is in parentheses. 
to elicit convulsions even at lethal doses. At large doses of levorphanol (300 
mg/kg), control animals showed only a brief period of behavioral spasticity 
that was accompanied by respiratory depression and death. These behavioral 
effects were not, however, associated with any seizure activity in the frontal 
cortex. 
The convulsions induced by the mu opiates differed in the ECS and 
control mice. In ECS animals, morphine and levorphanol induced clonic 
convulsions that were not lethal. In contrast, in control animals levorphanol 
did not produce any convulsions and the convulsions produced by morphine 
were almost always lethal (12 of 13). In the case of codeine, however, doses 
that produced convulsions were always lethal in both the control and ECS 
animals. 
The drug-induced convulsions observed in the ECS and control animals 
also differed in their response to naltrexone pretreatment (Fig. 2). In ECS 
animals, naltrexone (3 mg/kg) effectively blocked the convulsions induced 
by morphine (x2 = 5.12, P < O.OS), codeine (x2 = 5.6, P < 0.05) and 
levorphanol (x2 = 6.23, P < 0.05). In control animals, naltrexone failed to 
block the convulsions induced by morphine or codeine; however, large 
doses of naltrexone (30 and 100 mg/kg) prevented morphine from killing 
control animals during the observation period, an effect not seen with saline 
pretreatment. 
Experiment ZZ. In addition to showing an altered response to mu agonists, 
ECS animals showed a heightened sensitivity to the convulsant effects of 
kappa agonists. As seen in Fig. 3, ECS animals showed a half log unit shift 
to the left to both EKC (x2 = 8.04, P = 0.01, at 3 mg/kg) and (-)UM 
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FIG. 2. Percentage of mice convulsing to morphine, codeine, or levorphanol administered 5 
min after saline or different doses of naltrexone. All data points are based on six or more 
animals. All control animals were handled the same as ECS animals, but were not shocked. 
1071 (x2 = 6.56, P < 0.05, at 3 mg/kg). In contrast to the convulsions 
observed with mu opiates, EKC- and (-)UM 107 l-induced convulsions 
were not lethal in the control animals and naltrexone pretreatment blocked 
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FIG. 3. Percentage of ECS and control mice convulsing to EKC, (-)UM 1071, or (+)UM 
107 I 3 days afier seven EC!%. All control animals were handled the same as ECS animals, but 
were not shocked. All data points are based on six or more animals. 
the EKC- and (-)UM 107 l-induced convulsions in both the control as well 
as the ECS animals (Fig. 4). 
The convulsions induced by the kappa agonists were stereoselective in 
both the ECS and control animals (bottom of Fig. 3). Whereas 63% of the 
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nG. 4. Percentage of ECS and control mice convulsing to EKC or (-)UM 107 1 administered 
5 min after saline or different doses of naltrexone. All data points are based on six or more 
animals. All control animals were handled the same as ECS animals, but were not shocked. 
There was no difference between the two groups in the bottom figure.; the data points 
overlapped. 
ECS animals convulsed to 3 mg/kg (-)UM 107 1, none of the animals 
convulsed at doses of either 10 or 100 mg/kg (+)UM 107 1. A dose of 170 
mg/kg (+)UM 107 1 was needed to induce convulsions in these animals. 
Similarly, whereas 7 1% of the control mice convulsed to 10 mg/kg (-)UM 
107 1, no control animal convulsed at a dose of 100 mg/kg (+)UM 107 1, 
and only one of six convulsed at 170 mg/kg. It required a dose of 300 mg/ 
kg (+)UM 107 1 to reliably induce convulsions in control animals. It was 
apparent from these results that, in addition to being more sensitive to the 
levorotatory form of UM 107 1, ECS animals were more sensitive to (+)UM 
107 1 (170 mg/kg) compared with their controls (x2 = 10.37, P < 0.01). 
Experiment ZZZ. The changes that followed ECS, although not limited to 
opiates, were not observed with all nonopiate convulsant agents. Whereas 
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I%. 5. Percentage of ECS and control mice convulsing to metrazol (left) or strychnine (right) 
3 days after seven EC%. All controls were handled the same as ECS animals, but were not 
shocked. All data points were based on six or more animals. 
ECS animals were more sensitive to metrazol than control mice 
(x2 = 9.00, P < 0.01 at 50 mg/kg), they did not differ in their sensitivity to 
strychnine (Fig. 5). 
Experiment IV. The changes in responsiveness to morphine and EKC 
were found to vary with the number of convulsions, and the time between 
an animal’s last convulsion and drug testing. Animals receiving 23 ECSs 
showed a full log unit shift to the left in their responsiveness to EKC (Fig. 
6), compared with the only one-half log unit shift observed in animals 
receiving seven EC%. 
l 3DayFust 23ECS 
ITotal N’ZII 
o Controls ITotal N=l6l 
0.3 I.0 I.7 30 10.0 17.0 
EKC (m#b.@ 
FIG. 6. Percentage of ECS mice convulsing to EKC 3 days after 23 ECSs. Control animals 
were handled the same as ECS animals, but were not shocked. All data points are based on six 
or more animals. 
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Animals tested a month after their last of seven ECSs still showed changes 
in responsiveness to morphine. There was a small, but not significant (x 
= 0.71, n.s.), decline in the effect with time, as 50% of the ECS mice tested 
at 30 days convulsed to morphine (100 mg/kg) compared with 7 1% that 
convulsed to this dose 7 days after their last ECS. 
The induction of convulsions was necessary in producing these changes 
in opiate responsiveness, as repeated subconvulsive doses of EKC (1 mg/ 
kg) failed to produce a shift in morphine sensitivity. Convulsive doses of 
EKC (10 mg/kg) were, however, effective in producing changes in morphine 
responsiveness (Fig. 7). The magnitude of the changes observed with EKC 
(10 mg/kg) treatment was comparable to that seen following an equal 
number of electroconvulsive shocks. 
DISCUSSION 
The results demonstrate that mu and kappa agonists produce convulsions 
through different mechanisms in normal control animals. Mu agonists 
produce convulsions only at lethal doses, cannot be blocked by naltrexone, 
and their relative potencies are not consistent with established opiate 
receptor responses. Levorphanol is normally more potent than morphine, 
which in turn is more potent than codeine in producing known opiate 
receptor mediated responses, such as analgesia and locomotor changes (10, 
12, 15). We found, however, that codeine is most potent at producing 
convulsions in normal mice, followed by morphine, with levorphanol failing 
to elicit convulsions even at lethal doses. These results are consistent with 
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FIG. 7. Percentage of animals convulsing to morphine 3 days after a regimen of subconvulsive 
(1 mg/kg) or convulsive (10 mg/kg) doses of EKC. All data points are based on six or more 
animals. 
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other reports demonstrating that codeine produces convulsions at smaller 
doses than morphine (1) and that pretreatment with opiate antagonists is 
unable to block morphine’s convulsant effects (5, 16). In addition, Labella 
et al. (6) found that intraventicular injection of morphine produced seizures, 
but similar injections of levorphanol failed to do so even at large doses. 
Kappa agonists, on the other hand, produced convulsions that are not 
lethal, that can be blocked by naltrexone, and that are sensitive to the 
stereospecificity of the drug. Taken together, these results suggest that the 
convulsions observed with mu opiates are not mediated by an opiate 
receptor, whereas those induced by kappa agonists are a specific opiate 
receptor response. 
After a series of convulsions, ECS animals show a marked qualitative 
change in their response to mu agonists. Although mu agonists produce 
convulsions by a nonopiate mechanism in normal mice, our evidence 
indicates that following ECS the convulsions induced by mu opiates are 
consistent with an opiate receptor response. In electroconvulsed animals, 
responses to mu agonists can be blocked by naltrexone pretreatment and 
show a pattern of drug effects that is consistent with other established opiate 
receptor-mediated responses. Levorphanol is more effective in inducing 
convulsions than morphine in the ECS animals, which in turn is more 
effective than codeine. The relative effectiveness of these mu agonists is the 
opposite of that observed in normal control animals. Further, the changes 
in responsiveness to opiates appear to be long-lasting and can be detected 
for as long as 1 month after an animal’s last electroconvulsive shock. 
It is unlikely that the change in responsiveness to mu opiates represents 
a simple change in sensitivity for, if that were the case, naltrexone should 
have been able to block the convulsions in both the ECS and normal mice, 
rather than blocking the response only in animals that received ECS; the 
relative effectiveness of mu agonists should have been the same in both the 
ECS and normal mice, and it was not; and levorphanol should have been 
able to produce convulsions in both the ECS and normal mice, and it did 
not. In contrast, the changes observed in response to kappa agonists did 
reflect a change in sensitivity. Kappa agonists produced nonlethal convulsions 
in both the ECS and normal mice; the convulsions were blocked by 
naltrexone in both ECS and normal mice; and the convulsions showed 
stereoselectivity in both the ECS and normal mice. 
These changes in responsiveness to opiates may reflect changes in 
endogenous brain opioid systems. Consistent with this notion, Holaday et 
al. (4) reported that repeated ECS produced an increase in delta opioid 
receptor number without changing receptor affinity. Although an increased 
kappa receptor number or affinity might explain the enhanced sensitivity 
observed with kappa agonists, such an effect is unlikely to explain the 
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changes observed with mu agonists, for ECS animals show a qualitatively 
different response to these drugs. 
The induction of convulsions appears to be necessary in inducing these 
changes, as subconvulsive doses of EKC failed to produce a change in 
responsiveness to morphine. A change in morphine responsiveness was 
observed, however, when a convulsant dose of EKC was used. The EKC- 
induced convulsions produced a change in morphine responsiveness com- 
parable to that seen following an equal number of electroconvulsive shocks. 
This result is consistent with our earlier findings (9) which indicated that 
the changes were not specific to the kind of convulsion induced and could 
be produced by repeated metrazol, ECS, or kindled convulsions. The 
magnitude of the changes does depend, to some extent, on the number of 
convulsions induced; we found that animals receiving 23 ECSs showed a 
more pronounced change in sensitivity to EKC than animals given only 
seven ECSs. 
The changes in responsiveness to mu and kappa opiates cannot be 
explained exclusively on the basis of a general increase in seizure suscepti- 
bility. We found that whereas ECS animals are more sensitive to metrazol, 
they are not more sensitive to strychnine. Sangdee et al. (13) similarly 
reported that animals which have undergone ECS kindling were more 
sensitive to bicuculline and metrazol, but showed no change in their 
sensitivity to strychnine or picrotoxin. 
It is also unlikely that the changes observed with mu agonists are due to 
damage of the blood-brain barrier. An increased permeability in the blood- 
brain barrier is unlikely to explain the qualitative changes in responsiveness 
to mu opiates observed to follow ECS. Although changes in the permeability 
of the blood-brain barrier could have contributed to the increased sensitivity 
observed to kappa agonists, this does not seem highly likely as generalized 
damage of the blood-brain barrier might be expected to produce a global 
increased sensitivity to all convulsants, which was not found to be the case. 
Whether repeated ECS renders subjects more seizure-prone is controversial. 
Although it is claimed that psychiatric patients do not become more seizure- 
prone after a series of ECS (14), our research and that of others (11, 13) 
clearly indicates that animals may indeed be more seizure-prone, at least 
in response to certain drugs, after a series of convulsions. 
REFERENCES 
1. CORRADO, A. P., AND V. G. Lo~oo. 1961. An ekctrophysiological analysis of the 
convulsant action of morphine, codeine and thebaine. Arch. Inf. Pharmocudyn. 132: 
255-269. 
2. CREESE, I., AND S. H. SNYDER. 1975. Receptor binding and pharmacological activity of 
opiates in the guinea-pig intestine. J. Pharmacol. Exp. Ther. 194: 205-219. 
ECS AND RESPONSE TO OPIATES 237 
3. HEIN, D. W., A. W. YOUNG, S. HERLING, AND J. H. WOODS. 1981. Pharmacological 
analysis of the discriminative stimulus characteristics of ethylketazocine in the rhesus 
monkey. J. Pharmacol. Exp. Ther. 218: 7-15. 
4. HOLADAY, J. W., R. J. HITZEMANN, J. CURELL, F. C. TORTELLA, AND G. L. BELENKY. 
1982. Repeated electroconvulsive shock or chronic morphine treatment increases the 
number of H-DALA, D-Leu-enkephahn binding sites in rat brain membranes. Life Sci. 
31: 2359-2362. 
5. KOPPANYI, T., AND A. G. KARCZMAR. 1953. Nature of antagonism between N-allylnor- 
morphine (Nalline) and morphine. Fed. Proc. 12: 337. 
6. LABELLA, F. S., C. PINSKY, AND V. HAVLICEK. 1979. Morphine derivatives with diminished 
opiate receptor potency show enhanced central excitatory activity. Brain Res. 174: 263- 
271. 
7. MAGNAN, J., S. J. PATERSON, A. TAVANI, AND H. W. KOSTERLITZ. 1982. The binding 
spectrum of narcotic analgesic drugs with different agonist and antagonist properties. 
Nauyn-Schmiedeberg’s Arch. Pharmacol. 319: 197-205. 
8. MANSOUR, A., R. DOYLE, R. KATZ, AND E. S. VALENSTEIN. 1981. Long-lasting changes 
in morphine sensitivity following amygdaloid kindling in mice. Physiol. Eehav. 27: 
1117-1120. 
9. MANSOUR, A., AND E. S. VALENSTEIN. 1984. Morphine sensitivity and seizure proneness. 
Exp. Neural. 85: 346-357. 
10. PERT, C. B., AND S. H. SNYDER. 1973. Properties of opiate-receptor binding in rat brain. 
Proc. Natl. Acad. Sci. U.S.A. 70: 2243-2247. 
I I. RAMER, D., AND J. P. J. PANEL. 1977. Progressive intensification of motor seizures 
produced by periodic electroconvulsive shock. Exp. Neurol. 51: 42 l-433. 
12. RETHY, C. R., C. B. SMITH, AND J. E. VILLARREAL. 197 1. Effects of narcotic analgesics 
upon the locomotor activity and brain catecholamine content of the mouse. J. Pharmacol. 
Exp. Ther. 176: 472-479. 
13. SANGDEE, P., S. A. TURKANIS, AND R. KARLER. 1982. Kindling-like effect induced by 
repeated cornea1 electroshock in mice. Epilepsia 23: 47 l-479. 
14. SMALL, J. G., V. MILSTEIN, I. F. SMALL, AND P. H. SHARPLEY. 1981. Does ECT produce 
kindling? Biol. Psychiat. 16: 773-778. 
15. TERENIUS, L. 1974. Contribution of “receptor” affinity to analgesic potency. Comm. 
J. Pharm. Pharmacol. 26: 146-148. 
16. WINTER, C. A., AND L. FLATAKER. 1956. Effect of N-allyhtormorphine upon massive 
doses of narcotic drugs. Proc. Sot. Exp. Biol. Med. 93: 158-160. 
17. WOODS, J. H., C. B. SMITH, F. MEDZIHRADSKY, AND H. H. SWAIN. 1979. Pre&nicaJ 
testing of new analgesic drugs. Pages 429-445 in R. F. BEERS JR. AND E. G. BASSETT, 
Eds., Mechanism of Pain and Analgesic Compounds. Raven Press, New York. 
